Clinical Trial Detail

NCT ID NCT04008030
Title A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Patients With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) (CheckMate 8HW)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Bristol-Myers Squibb
Indications

colorectal cancer

Therapies

Nivolumab

Fluorouracil + Irinotecan + Leucovorin

Cetuximab

Fluorouracil + Leucovorin + Oxaliplatin

Bevacizumab

Ipilimumab + Nivolumab

Age Groups: senior adult

No variant requirements are available.